B of A Securities Maintains Buy on Lyra Therapeutics, Lowers Price Target to $11

Benzinga · 03/25 10:47
B of A Securities analyst Jason Gerberry maintains Lyra Therapeutics (NASDAQ:LYRA) with a Buy and lowers the price target from $12 to $11.